Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive molecular analysis of EORTC 22042-26042

Affiliations

• ¹ Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
• ² Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
• ³ Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany.
• ⁴ CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
• ⁵ Paul Scherrer Institute, Villigen PSI, Switzerland.
• ⁶ Department of Radiation Oncology, University Hospital and University of Zurich, Zurich, Switzerland.
• ⁷ Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
• ⁸ The Brain Tumor Center, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.
• ⁹ Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
• ¹⁰ Hôpitaux Universitaires de Genève, Geneva, Switzerland.
• ¹¹ ICO Badalona, Hospital Germans Trias I Pujol (Institut Catala D'Oncologia), Catalonia, Spain.
• ¹² Department of Neurosurgery, Amsterdam UMC, Amsterdam, The Netherlands.
• ¹³ EORTC Head Quarters, Brussels, Belgium.
• ¹⁴ Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany. Felix.Sahm@med.uni-heidelberg.de.
• ¹⁵ CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. Felix.Sahm@med.uni-heidelberg.de.